Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 6:15 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 9,939 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

NCT05849922
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Ocala, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 2 Interventional

Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients

NCT00013702
View directory record Official record
Conditions
Hepatitis B, HIV Infection
Interventions
Adefovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 4 Interventional

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445
View directory record Official record
Conditions
HIV Infections
Interventions
Truvada, Atazanavir, Ritonavir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 1 Interventional

Trial of Combination Therapy to Treat COVID-19 Infection

NCT04482686
View directory record Official record
Conditions
COVID, Covid-19, Corona Virus Infection, Coronavirus Infection, Coronavirus-19, SARS-CoV2, SARS-CoV Infection
Interventions
Ivermectin, Doxycycline Hcl, Zinc, Vitamin D3, Vitamin C
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 1, 2026, 6:15 PM EST
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19

NCT04474483
View directory record Official record
Conditions
COVID-19
Interventions
Melatonin, Placebo (Methylcellulose) capsule
Drug · Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 2 Interventional Results available

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

NCT00110305
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
9
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Nov 1, 2026, 6:15 PM EST
Active, not recruiting No phase listed Observational

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04387656
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

NCT01764256
View directory record Official record
Conditions
Rotavirus Infection
Interventions
P2-VP8 subunit rotavirus vaccine, placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

NCT04630002
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Nov 1, 2026, 6:15 PM EST
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 4 Interventional

MAKE IT CLEAN, Impact of Pocket Revision on the Rate of Infection and Other Complications in Patients Requiring Pocket Manipulation for Generator Replacement and/or Lead Replacement or Revision: A Prospective Randomized Study

NCT00599261
View directory record Official record
Conditions
Infection
Interventions
ICD/pacemaker pocket revision
Procedure
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Nov 1, 2026, 6:15 PM EST
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Nov 1, 2026, 6:15 PM EST
Completed Not applicable Interventional Results available

R5 Integrase Study in HIV-1 Naive Patients

NCT01204905
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir and Maraviroc in combination
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Nov 1, 2026, 6:15 PM EST
Completed Not applicable Interventional

The Digital Incentive Spirometer (DIS): Improving Adherence to Incentive Spirometry

NCT03686631
View directory record Official record
Conditions
Post-Op Infection, Adherence, Patient, Pulmonary Atelectasis, Incentive Spirometry, Post-Op Complication
Interventions
Smartphone Arm
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Nov 1, 2026, 6:15 PM EST
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 4 Interventional

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

NCT00187551
View directory record Official record
Conditions
HIV Infections
Interventions
Interruption of enfuvirtide, enfuvirtide interrupton
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Nov 1, 2026, 6:15 PM EST
Completed Not applicable Interventional

A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP

NCT00002053
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
Fisons
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 6:15 PM EST
Terminated Phase 1 Interventional

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

NCT00044837
View directory record Official record
Conditions
HIV Infections
Interventions
Medroxyprogesterone acetate, Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Nov 1, 2026, 6:15 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Syphilis Video Tool to Promote Knowledge and Testing in the ED

NCT00552539
View directory record Official record
Conditions
Syphilis
Interventions
'educational video'
Other
Lead sponsor
Jacobi Medical Center
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2007 · Synced Nov 1, 2026, 6:15 PM EST
Not yet recruiting Not applicable Interventional

Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test

NCT07875270
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
Interventions
Flu A/B/COVID-19 + RSV Multiplex Rapid Test
Device
Lead sponsor
CorDx, Inc.
Industry
Eligibility
6 Months and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

NCT00001056
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 1, 2026, 6:15 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Development of a New HIV Vaccine

NCT00051922
View directory record Official record
Conditions
HIV Infections
Interventions
PolyEnv1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Nov 1, 2026, 6:15 PM EST
Completed No phase listed Observational

Quality of Life in Children With HIV Infection

NCT00075153
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
10 Months to 25 Years
Enrollment
1,993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Nov 1, 2026, 6:15 PM EST